The U.S. FDA plans to offer ultra-fast review for three psychedelic drugs intended to treat mental health conditions. This move follows a directive from the Trump administration aimed at expediting access to experimental treatments.

The Food and Drug Administration said on Friday it will offer ultra-fast review to three psychedelic drugs being developed to treat mental health conditions, including depression, the latest indication of the Trump administration’s commitment to the experimental treatment approach. President Donald Trump signed an executive order last weekend directing the FDA and other federal agencies to speed access and loosen restrictions on psychedelics, a class of hallucinogenic drugs which remain illegal....